Sales by GlaxoSmithKline plc’s vaccines business declined by 29% in the second quarter of 2020, as COVID-19 pandemic lockdown measures limited visits to physicians but there were initial signs of a recovery in vaccination rates, reported CEO Emma Walmsley as the results were announced on 29 July.
Although GSK is maintaining its 2020 financial guidance (a decline in adjusted EPS of 1% to 4% at constant exchange...








